Natriuretic Peptide (ANP) vs TB-500
Your heart's natural fluid and pressure regulator, helping restore balance when fluid overload strikes.
A powerful fragment of thymosin beta-4 that acts like your body's repair signal—speeding up healing of muscles, tendons, and tissues by promoting cell migration and new blood vessel growth right where you need it most.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Natriuretic Peptide (ANP)
0.025–0.050 mcg/kg/min
TB-500
2–2.5 mg
Frequency
Natriuretic Peptide (ANP)
Once daily
TB-500
Twice weekly
Administration
Natriuretic Peptide (ANP)
Intravenous infusion (continuous) - standard hospital delivery method
TB-500
Subcutaneous injection
Cycle length
Natriuretic Peptide (ANP)
Ongoing/indefinite
TB-500
4-6 weeks
Onset speed
Natriuretic Peptide (ANP)
Moderate (1-2 weeks)
TB-500
Moderate (1-2 weeks)
Evidence level
Natriuretic Peptide (ANP)
Moderate human trials (Phase 1-2)
TB-500
Moderate human trials (Phase 1-2)
Benefit ratings
Acute Fluid Management
Hemodynamic Stabilization
Symptom Relief
Healing Speed
Tissue Repair
Anti-Scarring
Compound specifications
Natriuretic Peptide (ANP)
Molecular formula
C127H203N45O39S3
Molecular weight
3080.5 g/mol
Half-life
Approximately 15-30 minutes (IV administration)
Bioavailability
100% (intravenous administration)
CAS number
Variable depending on salt form; carperitide CAS: 120399-20-4
TB-500
Molecular formula
C38H68N10O14
Molecular weight
889.01 g/mol
Half-life
2-3 days (systemic)
Bioavailability
High via subcutaneous injection (~100%)
CAS number
885340-08-9
Dosing compared
Natriuretic Peptide (ANP)
Intravenous
0.0125 mcg/kg/min continuous infusion
Continuous IV infusion · Up to 72 hours
Very low starting dose used in some acute heart failure cases per Japanese Circulation Society guidance [4]. Hospital-only, titrated to blood pressure.
0.025-0.050 mcg/kg/min continuous infusion
Continuous IV infusion · Up to 72 hours
Guideline low-dose range for acute heart failure; associated with better 1-year outcomes than very-low dose [4]. Requires continuous hemodynamic monitoring.
TB-500
Subcutaneous
2-2.5 mg
Twice weekly · Loading phase, 4-6 weeks
Research peptide with no human trials of the fragment; [9] loading doses used in practice [6].
2-2.5 mg
Once weekly · Maintenance after loading
Maintenance dose used in practice following the loading phase [6].
Best suited for
Natriuretic Peptide (ANP)
Managing acute decompensated heart failure with fluid overload
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on managing acute decompensated heart failure with fluid overload. [8][9] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Relieving shortness of breath caused by pulmonary congestion
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on relieving shortness of breath caused by pulmonary congestion. [8] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Lowering elevated blood pressure in emergency cardiac situations
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on lowering elevated blood pressure in emergency cardiac situations. [5][11] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing the workload on the heart during acute episodes
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on reducing the workload on the heart during acute episodes. [11][12] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
TB-500
Athletes Recovering from Muscle Injuries
If you've pulled a hamstring, strained your back, or torn a muscle, TB-500 helps accelerate the healing process by promoting cell migration to the injury site and supporting new blood vessel growth. It's especially useful for injuries that just won't seem to fully heal [1][5].
Tendon and Ligament Problems
Tendons and ligaments are notoriously slow healers because they have poor blood supply. TB-500 promotes angiogenesis (new blood vessel formation) and helps repair these stubborn connective tissue injuries—think Achilles tendonitis, tennis elbow, or rotator cuff issues [5].
Post-Surgical Recovery
After surgery, your body needs to repair a lot of tissue quickly. TB-500 supports wound healing, reduces inflammation, and may help minimize scar tissue formation. Some protocols use it alongside traditional recovery to potentially speed up the healing timeline [1][4].
Chronic Inflammation and Slow Healers
Some people just heal slowly—whether due to age, diabetes, or other factors. TB-500 helps regulate the inflammatory response and promotes the cellular processes needed for tissue repair. It essentially tells your body to focus healing resources where they're needed most [1].
Side effects
Natriuretic Peptide (ANP)
Common
- Mild discomfort at treatment site
- Hypotension (excessively low blood pressure) requiring close monitoring
- Headache and dizziness from sudden blood pressure changes
- Weakness and fatigue during or shortly after treatment
- Nausea and gastrointestinal discomfort
- Decreased kidney function temporarily, requiring follow-up monitoring
- Tremors or shaking sensations
- Atrial fibrillation (irregular heartbeat) in some patients
- Abdominal pain
- Injection site reactions if administered intravenously
- Renal dysfunction with prolonged use, especially in elderly patients
Serious
- Severe allergic reaction
TB-500
Common
- Injection site redness
- Mild fatigue or lethargy
- Mild headache
- Slight flushing
Uncommon
- Head rush or lightheadedness
- Temporary nausea
Serious
- Allergic reaction
Safety & evidence
Natriuretic Peptide (ANP)
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Exogenous ANP demonstrates excellent safety in Phase II/III cardiac decompensation trials with rapid clearance (2-minute half-life) [6][10] providing inherent safety margins. Hypotension is the expected primary effect, managed through continuous hemodynamic monitoring and dose titration. [9][10] No serious adverse events or carcinogenicity observed in 500+ trial participants. Receptor desensitization with prolonged continuous infusion [5] requires periodic treatment breaks or dose adjustments.
Contraindications
- Severe kidney failure with very low glomerular filtration rate
- Recent or ongoing treatment with certain blood pressure medications that may cause dangerous drops in pressure
- Acute coronary syndrome or recent heart attack where vasodilation could be harmful
- Severe hypotension or cardiogenic shock without proper supportive care
- Allergies to ANP, carperitide, or any components of the pharmaceutical formulation
TB-500
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
TB-500 has shown a good safety profile across preclinical studies and limited human research. It's a fragment of thymosin beta-4, a naturally occurring protein in your body involved in healing. Most side effects are mild and transient, primarily injection site reactions. However, large-scale clinical trials are still needed to fully establish its safety profile in humans [1].
Contraindications
- Pregnancy or planning to become pregnant
- Currently breastfeeding
- Active cancer or history of cancer
- Known allergy to peptide components
- Children and adolescents
Which is right for you?
Choose Natriuretic Peptide (ANP) if...
- Managing acute decompensated heart failure with fluid overload
- Relieving shortness of breath caused by pulmonary congestion
- Lowering elevated blood pressure in emergency cardiac situations
- Reducing the workload on the heart during acute episodes
Choose TB-500 if...
- Accelerating injury recovery
- Tendon and ligament healing
- Reducing chronic inflammation
- Post-surgical recovery support